Abstracts tagged "gout and outcomes"

Abstract Number: 203 • 2016 ACR/ARHP Annual Meeting
Allopurinol Dose Escalation and Mortality Among Patients with Gout: A National Propensity-Matched Cohort Study
Brian W Coburn^1,2, Kaleb Michaud³, Debra A Bergman² and Ted R Mikuls^4,5, ¹Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Allopurinol Dose Escalation and Mortality among Patients with Gout: A National Propensity-Matched Cohort Study Background/Purpose: Numerous epidemiologic studies show that hyperuricemia and gout are associated…
Abstract Number: 2356 • 2015 ACR/ARHP Annual Meeting
Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)
JoAnne Foody¹, Robin Turpin², Beni Tidwell³ and Kathy Schulman⁴, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, ³ORS, Shrewsbury, MA, ⁴Outcomes Research Solutions, Inc., Waltham, MA
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and oxidative stress in the vasculature, both of which are cardiovascular disease (CVD) risk factors. However,…
Abstract Number: 2121 • 2014 ACR/ARHP Annual Meeting
Real-World Cost Comparison of Urate Lowering Therapies in Patients with Gout and Moderate to Severe Chronic Kidney Disease
Ghaith Mitri¹, Eric Wittbrodt¹, Robin Turpin¹, Beni Tidwell² and Kathy Schulman², ¹Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, ²Outcomes Research Solutions, Inc., Waltham, MA
Background/Purpose Gout flare prevention relies heavily on urate-lowering therapies (ULT) such as allopurinol (ALP) and febuxostat (FBX) but clinical decision-making in patients with moderate to…